The Food and Drug Administration (FDA) has announced a nationwide recall affecting over 67,000 cases of Power Stick roll-on antiperspirant deodorants. The enforcement action was initiated by manufacturer A.P. Deauville following concerns about deviations from Current Good Manufacturing Practices (cGMP), which are mandatory quality standards for facilities that produce regulated products like deodorants. According to the official FDA enforcement report, the recall was formally initiated on July 10 and covers a range of Power Stick variants sold throughout the United States.
The affected products include three specific variants of Power Stick deodorants: the "power fresh"-scented Power Stick for Her Roll-On Antiperspirant Deodorant, the "spring fresh"-scented Power Stick Invisible Protection Roll-On Antiperspirant Deodorant, and the Power Stick Original Nourishing Invisible Protection Roll-On Antiperspirant Deodorant. All three were identified as having been manufactured in violation of FDA’s cGMP guidelines, though the agency did not specify the exact nature of the deviations.
The lot numbers associated with the Power Stick for Her deodorant include 032026B011, 032226B031, 051626C241, 061526C882, 071226D371, 071226D381, 082526E341, and 082826E402. Meanwhile, the lot numbers for the Power Stick Invisible Protection Roll-On Antiperspirant are 031726A991, 041226B561, 062026C901, 062026C911, 071026D351, 071026D361, 071326D391, and 111626G231. For the Power Stick Original Nourishing Invisible Protection, the recalled lot numbers include 101225D781, 032926B281, 032826B221, 041126B531, 062226D011, 070626D301, 070626D333, 111026G051, 111326G091, and 111626G221.
The company behind these products, A.P. Deauville, is headquartered in Easton, Pennsylvania, a city located near the eastern edge of the state and bordering New Jersey. According to information available on the company's website, all of its deodorant products are manufactured at a facility that is regulated by the FDA. While the recall was triggered by manufacturing compliance issues rather than contamination or direct health risks, cGMP deviations are serious as they pertain to the quality and safety controls in place during production.
The recalled deodorants had been distributed widely across retail chains and e-commerce platforms, including discount and dollar stores as well as major online retailers. While no adverse events have been publicly reported as of now, the FDA’s move to publish the enforcement report is meant to caution both retailers and consumers about the potential risks associated with products manufactured under substandard practices. Consumers in possession of these products are advised to discontinue use and either return them to the point of purchase or dispose of them safely.
A.P. Deauville produces a range of personal care items in addition to antiperspirants, including shampoos, conditioners, body lotions, facial wipes, and body washes. The scope of this recall is currently limited to the specific deodorant products and lot numbers mentioned in the FDA enforcement report.
It’s important to note that despite some initial confusion, retail giant Walmart was not involved in the sale or distribution of these recalled deodorant products, and the story has been updated to reflect that clarification. The focus remains on ensuring that any potentially affected units are swiftly removed from the market to maintain consumer safety and regulatory compliance.
This recall once again underscores the importance of stringent adherence to quality assurance measures and federal manufacturing standards, especially for consumer products that are used daily and applied directly to the skin. The FDA is expected to continue monitoring A.P. Deauville’s compliance and production practices to prevent similar issues from arising in the future.
